FI106927B - Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen - Google Patents

Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen Download PDF

Info

Publication number
FI106927B
FI106927B FI960979A FI960979A FI106927B FI 106927 B FI106927 B FI 106927B FI 960979 A FI960979 A FI 960979A FI 960979 A FI960979 A FI 960979A FI 106927 B FI106927 B FI 106927B
Authority
FI
Finland
Prior art keywords
antigen
antibody
cells
cell
antibodies
Prior art date
Application number
FI960979A
Other languages
English (en)
Finnish (fi)
Other versions
FI960979A (sv
FI960979A0 (sv
Inventor
Randolph J Noelle
Teresa M Foy
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI106927(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of FI960979A0 publication Critical patent/FI960979A0/sv
Publication of FI960979A publication Critical patent/FI960979A/sv
Application granted granted Critical
Publication of FI106927B publication Critical patent/FI106927B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Claims (11)

1. Förfarande för in vitro-bestämning av huruvida en antigen är en TD-antigen (tymusberoende antigen) eller en TI-2-antigen (tymusoberoende antigen), känne-tecknat av att T- och B-cellema exponeras för en sammansättning innehällandc 5 antigen och gp39-antagonist, och av bestämning av huruvida de humora immunres-ponsema undertrycks av näninda antigen.
2. Förfarande enligt patentkrav 1, kännetecknat av att antagonisten är en anti-gp-39-antikropp.
3. Förfarande enligt patentkrav 1, kännetecknat av att TD-antigenen är ett pro-10 tein.
4. Förfarande enligt patentkrav 1, kännetecknat av att TD-antigenen är en antikropp.
5. Förfarande enligt patentkrav 1, kännetecknat av att TD-antigenen exprimeras pä cellytan, 15
6. Förfarande enligt patentkrav 1, kännetecknat av att antagonisten är en gp39- ligand i löslig form.
7. Förfarande enligt patentkrav 1, kännetecknat av att antagonisten är en löslig CD40-fusionsprotein.
8. Förfarande enligt patentkrav 2, kännetecknat av att anti-gp39-motkroppen är ;' ·,. 20 en kimerisk monoklonal motkropp.
··· » » ♦ ’·’/ 9. Förfarande enligt patentkrav 2, kännetecknat av att anti-gp39-motkroppen är » · ’ · · ·* en humaniserad monoklonal motkropp. • · · • · · • · ·
10· Förfarande enligt patentkrav 2, kännetecknat av att anti-gp39-motkroppen är en monoklonal motkropp 24-31 (ATCC HB 11712). '· * 25
11. Förfarande enligt patentkrav 2, kännetecknat av att anti-gp39-motkroppen är en monoklonal motkropp 89-76 (ATCC HB 11713). <
FI960979A 1993-09-02 1996-03-01 Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen FI106927B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US11599093 1993-09-02
US23292994 1994-04-25
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity
US9409872 1994-09-02

Publications (3)

Publication Number Publication Date
FI960979A0 FI960979A0 (sv) 1996-03-01
FI960979A FI960979A (sv) 1996-04-30
FI106927B true FI106927B (sv) 2001-05-15

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960979A FI106927B (sv) 1993-09-02 1996-03-01 Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen

Country Status (14)

Country Link
EP (1) EP0742721B1 (sv)
JP (1) JP2840131B2 (sv)
CN (1) CN1137726C (sv)
AT (1) ATE179616T1 (sv)
AU (3) AU7643094A (sv)
DE (1) DE69418349T2 (sv)
DK (1) DK0742721T3 (sv)
ES (1) ES2134954T3 (sv)
FI (1) FI106927B (sv)
GR (1) GR3030762T3 (sv)
IL (1) IL110852A (sv)
NO (1) NO321037B1 (sv)
NZ (1) NZ273208A (sv)
WO (1) WO1995006480A1 (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
CA2089611A1 (en) * 1992-02-17 1993-08-18 Toshiro Yanase Antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
FI960979A (sv) 1996-04-30
JP2840131B2 (ja) 1998-12-24
AU7643094A (en) 1995-03-22
ES2134954T3 (es) 1999-10-16
AU1422099A (en) 1999-04-01
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
NZ273208A (en) 2000-12-22
DE69418349D1 (de) 1999-06-10
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
IL110852A (en) 1999-05-09
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06
NO960863D0 (no) 1996-03-01
NO321037B1 (no) 2006-03-06
ATE179616T1 (de) 1999-05-15
EP0742721A1 (en) 1996-11-20
JPH09502184A (ja) 1997-03-04
IL110852A0 (en) 1994-11-28
CN1137726C (zh) 2004-02-11
FI960979A0 (sv) 1996-03-01
AU734853B2 (en) 2001-06-21
AU2004240180B2 (en) 2007-08-09
DK0742721T3 (da) 1999-11-01

Similar Documents

Publication Publication Date Title
FI118792B (sv) Användningar av inducering T-celltorerans med hänsyn till vävnads- eller organtransplantat
FI106306B (sv) Förfarande för framställning av anti-GP-39-antikropp
US5942229A (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent
FI106927B (sv) Förfarande för bestämning av huruvida en antigen är en TD-antigen eller en TI-2-antigen
AU779647B2 (en) Methods of prolonged suppression of humoral immunity
AU678532C (en) Methods for inducing antigen-specific T cell tolerance
HU220192B (hu) Gyógyszerkészítmények a humorális immunitás gátlására